

**NOTICE OF DATE OF ANNUAL GENERAL MEETING AND OTHER
RELEVANT DATES**

Melbourne, Australia – 29 August 2024: Pursuant to ASX Listing Rule 3.13.1 Percheron Therapeutics Limited (ASX: PER) (**Percheron** or the **Company**) is pleased to advise the following details in relation to the Company's forthcoming Annual General Meeting (**AGM**).

Date and time for the AGM	Thursday 21 November 2024 10:00am (AEDT)
Date of Notice of Meeting dispatch	Friday 18 October 2024
Last date for receipt of nomination as a Director	Friday 4 October 2024

Further details in relation to the AGM, including items of business to be voted upon by shareholders, and instructions on how shareholders may attend and vote at the meeting, will be provided in the Notice of Meeting. The Company's Appendix 4E, together with the FY 2024 Annual Report were released to the ASX on 29 August 2024 and can be accessed and downloaded from the Company's website here www.percherontx.com.

Shareholders may obtain a hard copy of the Annual Report by emailing a request to the Company at info@percherontx.com.

The Company looks forward to shareholders participating at this year's AGM.

ENDS ~

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is ATL1102, an antisense oligonucleotide targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in 2H CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

***This announcement has been authorised for release to the Australian Securities Exchange
by Ms Deborah Ambrosini, Company Secretary, Percheron Therapeutics.***
